Medically induced myopathia;Medikamenteninduzierte myopathien

Nervenarzt

Volumn 77, Issue 6, 2006, Pages 682-693

  Finsterer, J ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Drugs; Intoxication; Neuromuscular disorders; Side effect

Indexed keywords

AMPICILLIN; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BUPIVACAINE; CARDIOTONIC AGENT; CHLOROQUINE; CLARITHROMYCIN; CYTOSTATIC AGENT; DALFOPRISTIN; DAPTOMYCIN; DIPHENHYDRAMINE; DOXYLAMINE; ERYTHROMYCIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETAMINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PENTAZOCINE; PROPOFOL; PSYCHOTROPIC AGENT; QUINUPRISTIN; ROPIVACAINE; UNINDEXED DRUG;

BLOOD ANALYSIS; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CORTICOSTEROID INDUCED MYOPATHY; DRUG INDUCED DISEASE; DYSPHAGIA; DYSPNEA; DYSTROPHY; ELECTROMYOGRAPHY; FASCICULATION; FATIGUE; HUMAN; HYPERTHERMIA; HYPOREFLEXIA; KIDNEY FAILURE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CRAMP; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA; MYOGLOBINURIA; MYOPATHY; MYOSITIS; NECROSIS; NEUROLOGIC EXAMINATION; NEUROPATHY; PARESIS; PATHOGENESIS; PSYCHOMOTOR RETARDATION; REVIEW; RHABDOMYOLYSIS; URINALYSIS;

HUMANS; MUSCULAR DISEASES; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33746402882     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-006-2080-4     Document Type: Review

References (103)

1. Bannwarth B (2002) Drug-induced myopathies. Expert Opin Drug Saf 1:65-70
2. Walsh RJ, Amato AA (2005) Toxic myopathies. Neurol Clin 23:397-428
3. Melli G, Chaudhry V, Cornblath DR (2005) Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 84:377-385
4. Le Quintrec JS, Le Quintrec JL (1991) Drug-induced myopathies. Baillieres Clin Rheumatol 5:21-38
5. Schoser BG, Pongratz D (2005) Lipid lowering drug and other toxic myopathies. Internist (Berl) 46:1198-1206
6. Coquet M, Bannwarth B, Henin D (2001) Drug-induced and toxic myopathies. Rev Prat 51:278-283
7. Nasu K, Sugano T, Yoshimatsu J et al. (2005) Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy. Gynecol Obstet Invest 61:53-55
8. Baker SK, Tarnopolsky MA (2005) Statin-associated neuromyotoxicity. Timely Top Med Cardiovasc Dis 9:E26
9. Franc S, Bruckert E, Giral P et al. (1997) Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents. Presse Med 26:1855-1858
10. Voermans NC, Lammens M, Wevers RA et al. (2005) Statin-disclosed acid maltase deficiency. J Intern Med 258:196-197
11. Köller H, Neuhaus O, Schroeter M et al. (2005) Myopathies under therapy with lipid-lowering agents. Nervenarzt 76:212-217
12. Bruggemann W, Herath H, Ferbert A (1996) Follow-up and immunologic findings in drug-induced myasthenia. Med Klin (Munich) 91:268-271
13. Fraenkel PG, Rutkove SB, Matheson JK et al. (2002) Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 25:373-378
14. Owczarek J, Jasinska M, Orszulak-Michalak D (2005) Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57:23-34
15. Kanda F, Okuda S, Matsushita T et al. (2001) Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 56[Suppl 1]:24-28
16. Kumar S (2003) Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India 51:554-556
17. Adamson R, Rambaran C, D'Cruz DP (2005) Anabolic steroid-induced rhabdomyolysis. Hosp Med 66:362
18. Polsonetti BW, Joy SD, Laos LF (2002) Steroid-induced myopathy in the ICU. Ann Pharmacother 36:1741-1744
19. Finsterer J, Schäfer J, Reichmann H (2004) Muskelerkrankungen und Myasthenien. In: Stefan H, Mamoli B (Hrsg) Aktuelle Therapie in der Neurologie. Ecomed, Landsberg/Lech
20. Roten L, Schoenenberger RA, Krahenbuhl S et al. (2004) Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 38:978-981
21. Wilke RA, Moore JH, Burmester JK (2005) Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 15:415-421
22. Hodel C (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 128:159-168
23. Finsterer J (2003) Fibrate and statine myopathy. Nervenarzt 74:115-122
24. Finsterer J, Stollberger C (2005) Myalgia, hyper-CK-aemia, and hypocoagulability in a patient under rosuvastatin and warfarin. Eur J Neurol 12:660
25. Mubhtar RY, Reckless JP (2005) Statin-induced myositis: a commonly encountered or rare side effect? Curr Opin Lipidol 16:640-647
26. Fauchais AL, Iba Ba J, Maurage P et al. (2004) Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne 25:294-298
27. Phillips PS, Haas RH, Bannykh S et al. (2002) Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585
28. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690
29. Farswan M, Rathod SP, Upaganlawar AB et al. (2005) Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. Indian J Exp Biol 43:845-848
30. Prueksaritanont T, Subramanian R, Fang X et al. (2002) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512
31. Morimoto S, Fujioka Y, Tsutsumi C et al. (2005) Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. Am J Med Sci 329:211-213
32. Bhatia GS, Lip GY (2004) Atrial fibrillation post-myocardial infarction: frequency, consequences, and management. Curr Heart Fail Rep 1:149-155
33. de Denus S, Spinler SA (2003) Amiodarone's role in simvastatin-associated rhabdomyolysis. Am J Health Syst Pharm 60:1791
34. Kamaliah MD, Sanjay LD (2001) Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 42:368-372
35. Authier FJ, Chariot P, Gherardi RK (2005) Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 32:247-260
36. Jarvis B, Faulds D (1999) Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58:101-141
37. Fodale V, Mazzeo A, Pratico C et al. (2005) Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia 60:806-810
38. Dalakas MC, Illa I, Pezeshkpour GH et al. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322:1098-1105
39. Miro O, Lopez S, Cardellach F et al. (2005) Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir Ther 10[Suppl 2]:M73-M81
40. Fujii Y, Arimura Y, Takahashi N et al. (2003) A case of Behcet's disease associated with neuromyopathy induced by combination therapy with colchicine and cyclosporin. Ryumachi 43:44-50
41. Kusus M, Stapleton DD, Lertora JJ et al. (2000) Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 320:394-397
42. Locsey L, Asztalos L, Kincses Z et al. (1997) Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants. Int Urol Nephrol 29:95-106
43. Sochman J, Podzimkova M (2005) Not all statins are alike: induced rhabdomyolysis on changing from one statin to another one. Int J Cardiol 99:145-146
44. Geilen CC, Arnold M, Orfanos CE (2001) Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 144:583-586
45. Greiner K, Varikkara M, Santiago C et al. (2002) Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe 99:691-694
46. Piccoli GB, Rossetti M, Guarena C et al. (2004) Myalgia: an uncommon or underestimated side effect of mycophenolate mophetil after transplantation? Nephrol Dial Transplant 19:1940-1942
47. Hardinger KL, Wang CD, Schnitzler MA et al.(2002) Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2:867-871
48. Neu AM, Furth SL, Case BW et al. (1997) Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). Clin Transplant 11:412-414
49. Veroux P, Veroux M, Puliatti C et al. (2003) Severe neurotoxicity in tacrolimus-treated living kidney transplantation in two cases. Urol Int 71:433-434
50. Shimazaki C, Ochiai N, Uchida R et al. (2003) Intramuscular edema as a complication of treatment with imatinib. Leukemia 17:804-805
51. Gabrielli M, Santarelli L, Serricchio M et al. (2003) Acute reversible rhabdomyolysis during Interferon alpha2B therapy for hepatitis C. Am J Gastroenterol 98:940
52. Kumar L, Gangadharan VP, Rao DR et al. (2005) Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: results of a multicentre trial from India. Nat Med J India 18:66-70
53. Ozdag F, Akar A, Eroglu E et al. (2001) Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. J Dermatolog Treat 12:167-169
54. Finsterer J, Kanzler M, Weinberger A (2003) Sirolimus myopathy. Transplantation 76:1773-1774
55. Morimoto S, Fujioka Y, Tsutsumi C et al. (2005) Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. Am J Med Sci 329:211-213
56. Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. Oncologist 9:271-281
57. Wilbur K, Makowsky M (2004) Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 24:1784-1792
58. Sugie M, Kuriki A, Arai D et al. (2005) A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate. No To Shinkei 57:785-790
59. Besser R, Treese N, Bohl J et al. (1994) Clinical, neurophysiologicand biopsy findings in neurotoxic amiodarone syndrome. Med Klin (Munich) 89:367-372
60. Bonnet C, Zabraniecki L, Bertin P et al. (1995) Amiodarone-induced neuromyopathy mimicking po-lymyositis. Rev Rhum Engl Ed 62:468
61. Carella F (1989) Myopathy and accumulation of amiodarone. Muscle Nerve 12:514
62. Clouston PD, Donnelly PE (1989) Acute necrotising myopathy associated with amiodarone therapy. Aust N Z J Med 19:483-485
63. Silva Oropeza E, Peralta Rosado HR, Valero Elizondo C et al. (1997) A case of amiodarone and neuromyopathy. Rev Invest Clin 49:135-139
64. Carella F (1989) Myopathy and accumulation of amiodarone. Muscle Nerve 12:514
65. Carella F, Riva E, Morandi L et al. (1987) Myopathy during amiodarone treatment: a case report. Ital J Neurol Sci 8:605-608
66. Zink W, Graf BM (2004) Local anesthetic myotoxicity. Reg Anesth Pain Med 29:333-340
67. Zink W, Bohl JR, Hacke N et al. (2005) The long term myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blocks. Anesth Analg 101:548-554
68. Finsterer J, Haberler C, Schmiedel J (2005) Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia. Clin Neuropharmacol 28:148-149
69. Hansen TG (2005) Propofol infusion syndrome in children. Ugeskr Laeger 167:3672-3675
70. Weiner AL, Vieira L, McKay CA et al. (2000) Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 18:447-451
71. Hadad E, Weinbroum AA, Ben-Abraham R (2003) Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med 10:149-154
72. Finsterer J (2003) Current concepts in malignant hyperthermia. J Clin Neuromuscul Dis 4:64-74
73. Kampe S, Krombach JW, Diefenbach C (2003) Muscle relaxants. Best Pract Res Clin Anaesthesiol 17:137-146
74. Burnham EL, Moss M, Ziegler TR (2005) Myopathies in critical illness: characterization and nutritional aspects. J Nutr 135:1818S-1823S
75. Latronico N, Peli E, Botteri M (2005) Critical illness myopathy and neuropathy. Curr Opin Crit Care 11:126-132
76. Hudson LD, Lee CM (2003) Neuromuscular sequelae of critical illness. N Engl J Med 348:745-747
77. Hund E (1999) Myopathy in critically ill patients. Crit Care Med 27:2544-2547
78. Khilnani GC, Bansal R (2004) Neuromuscular weakness in critically ill. J Assoc Physicians India 52:131-136
79. Riggs JE, Pandey HK, Schochet SS Jr (2004) Critical illness myopathy associated with hyperthyroidism. Mil Med 169:71-72
80. Bercker S, Weber-Carstens S, Deja M et al. (2005) Critical illness polyneuropathy and myopathy in patients with acute respiratory distress syndrome. Crit Care Med 33:711-715
81. Al-Jumah MA, Awada AA, AI-Ayafi HA et al. (2004) Neuromuscular paralysis in the intensive care unit. Saudi Med J 25:474-477
82. Friedrich O, Hund E, Weber C et al. (2004) Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 251:53-65
83. Friedrich O, Hund E, Weber C et al. (2004) Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 251:53-65
84. Mohammadianpanah M, Omidvari S, Mosalaei A et al. (2004) Cisplatin-induced hypokalemic paralysis. Clin Ther 26:1320-1323
85. Ardavanis AS, loannidis GN, Rigatos GA (2005) Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res 255:523-525
86. Maubec E, Oberlin O, Belhadj K et al. (2001) Subcutaneous inflammatory edema induced by MINE chemotherapy. Ann Dermatol Venereol 128:534-537
87. Bezjak A, Tu D, Bacon M et al. (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22:4595-4603
88. Oh DY, Kim JH, Kim DW et al. (2005) CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. Support Care Cancer 14:103-108
89. Smith RE, Anderson SJ, Brown A et al. (2002) Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer 3:333-340
90. Thongprasert S, Napapan S, Charoentum C et al. (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279-281
91. Oskay T, Kutluay L, Ozyilkan O (2002) Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera. Eur J Dermatol 12:586-588
92. Crayton H, Bohlmann T, Sufit R et al. (1991) Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma. Clin Exp Rheumatol 9:525-528
93. Van Gerpen JA, McKinley KL (2002) Leuprolide-induced myopathy. J Am Geriatr Soc 50:1746
94. Terao T, Hori H, Nakamura J (1999) L-tryptophaninduced eosinophilia-myalgia syndrome, Chinese restaurant syndrome. Ryoikibetsu Shokogun Shirizu 27:650-653
95. Sullivan EA, Staehling N, Philen RM (1996) Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases. J Rheumatol 23:1784-1787
96. Haas CE, Magram Y, Mishra A (2003) Rhabdomyolysis and acute renal failure following an ethanol and diphenhydramine overdose. Ann Pharmacother 37:538-542
97. O-Lee T, Stewart CE 4th, Seery L et al. (2005) Fluoroquinolone-induced arthralgia and myalgia in the treatment of sinusitis. Am J Rhinol 19:395-399
98. Carver PL, Whang E, VandenBussche HL et al. (2003) Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 23:159-164
99. Matsuda Y, Nagayoshi Y, Kirihara N (2002) Rhabdomyolysis during prolonged intravenous tocolytic therapy. J Perinat Med 30:514-516
100. Schara U, Mortier W (2005) Neuromuscular diseases 2: muscular dystrophies (MD). Nervenarzt 76:219-237
101. Wakata N, Sugimoto H, Iguchi H et al. (2001) Bupivacaine hydrochloride induces muscle fiber necrosis and hydroxyl radical formation-dimethyl sulphoxide reduces hydroxyl radical formation. Neurochem Res 26:841-844
102. Jouglard J, Kozak-Ribbens G, de Haro L et al. (1996) Research into individual predisposition to develop acute rhabdomyolysis attributed to fenoverine. Hum Exp Toxicol 15:815-820
103. Kottlors M, Jaksch M, Ketelsen UP et al. (2001) Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 11:757-759